INVION | PoC III: COMBINATION WITH IMMUNE CHECKPOINT INHIBITORS Melbourne (Australia) 30 May 2022: Invion Limited (ASX: IVX) is please to announce the findings from the third Proof-Of-Concept (PoC) study undertaken by its research partner, Hudson Institute of Medical Research (Hudson Institute). The PoC was specifically designed to evaluate whether INV043 can be used in…
Read more
